Abstract:Ethnopharmacological relevance: Kumu injection (KMI) is made from the branches and stems of Picrasma quassiodes (D. Don) Benn. and has been used clinically for the treatment of upper respiratory tract infection, acute tonsillitis, enteritis and bacillary dysentery. 3-methylcanthin-2,6-dione, 5-hydroxy-4-methoxycanthin-6-one, 4,5-dimethoxycanthin-6-one are the active ingredients of KMI because of its therapeutic effects.Aim of the study: To develop a LC-MS/MS method for simultaneous determination of three active canthinone alkaloids (4,5-dimethoxycanthin-6-one, 5-hydroxy-4-methoxycanthin-6-one and 3-methylcanthin-2,6-dione) in rat plasma and for the pharmacokinetic study of them after administered of KMI to rats.Materials and methods: Rats were divided into 5 groups (n=5 per group), 3 groups administered intramuscularly with a single dose of KMI at 030, 0.45 and 0.90 mL/kg respectively, and the other 2 groups administered intragastically or intravenously a single dose of KMI at 0.9 mL/kg respectively. The concentrations of 4,5-dimethoxycanthin-6-one, 5-hydroxy-4-methoxycanthin-6-one and 3-methylcanthin-2,6-dione in plasma were determined by the established LC-MS/MS method at different time points and the pharmacokinetic parameters were estimated by non-compartmental analysis.Results: Pharmacokinetic results indicated that all of the alkaloids were absorbed rapidly and 3-methylcanthin-2,6-dione was eliminated fastest in rats. After intramuscular administration of KMI to rats, the absolute bioavailability is excellent, and the pharmacokinetic profiles are characterized by the first order kinetics.Conclusion: The established method is suitable for the quantitation of the three alkaloids in rat plasma. And this pharmacokinetic study suggested that intramuscular injection of KMI was suitable in clinical usage. (C) 2016 Elsevier Ireland Ltd. All rights reserved.

Pharmacokinetics of N-methylcantharidimide after Intragastral and Intravenous Administration

Gastrointestinal Absorption Kinetics of Methylcantharidimide in Rats

Determination of Norcantharidin in Mouse Tissues by Liquid Chromatography Coupled to Tandem Mass Spectrometry and its Tissue Distribution Study

[Studies on the Liver Targeting of Norcantharindin Microemulsion].

In vivo pharmacokinetics and distribution of nimodipine microemulsion injection in mice

Study on the Distribution and Liver Targeting of Norcantharidin Nanoparticles in Mice

Study on Absorption Mechanism and Anti-tumor Pharmacodynamics in Mice of Norcantharidin Loaded N-Galactosylated Chitosan Nanoparticles

Study on pharmacokinetics of geniposide in mice administrated by Xingnaojing microemulsion and mPEG2000-PLA modified Xingnaojing microemulsion

Experimental study of intraperitoneal chemotherapy with mitomycin C bound to carbon nanopaticles

Effect of Injection Routes on Pharmacokinetics and Lactone/carboxylate Equilibrium of 9-Nitrocamptothecin in Rats.

Bioaccumulation And Toxicity Of Carbon Nanoparticles Suspension Injection In Intravenously Exposed Mice

[Pharmacokinetic Study of Intraperitoneal Chemotherapy with Mitomycin C Bound to Activated Carbon Particles].

The Pharmacokinetics and Bioavailability of Three Canthinone Alkaloids after Administration of Kumu Injection to Rats.

[Study on pharmacokinetics of matrine by intramuscular administration in rat].

Separation and Identification of Norcantharidin Metabolites in Vivo by GC–MS Method

Study on Pharmacokinetic Profile of PVP-coated Norcantharidin-Chitosan Nanoparticles in Rats by HPLC-MS/MS

Tissue Distribution of Cisplatin-Loaded Magnetic Nanomedicine in Mice

Study on Body Distribution and Hepatic Targeting Tendency of Galactosyl Adriamycin Bovine Serum Albumin Nanoparticles in Mice by Radioisotope Tracing

Study on the Physicochemical Properties and the Intestinal Absorption Kinetics of Norcantharidin in Rats

Oral Versus Intraperitoneal Administration of Irinotecan in the Treatment of Human Neuroblastoma in Nude Mice.

Studies on Pharmacokinetics of Lactosyl-norcantharidin Nanoparticals in Rats